b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">31219021</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>09</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>07</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Print">1550-7033</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>15</Volume>\n                    <Issue>8</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Aug</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of biomedical nanotechnology</Title>\n                <ISOAbbreviation>J Biomed Nanotechnol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Improved Stability and Enhanced Anti-Tumor Activity of Hyaluronic Acid Modified ES2-AF Nanoparticle-Like Conjugate.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1781-1791</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1166/jbn.2019.2808</ELocationID>\n            <Abstract>\n                <AbstractText>The growth, migration and spread of malignant tumors requires a large number of new blood vessels to supply nutrients. In our previous study, it was found that the hyaluronic acid (HA) modified novel antiangiogenic peptide ES2-AF has better solubility, longer half-life, stronger targeting than non-modified ES2-AF, and it significantly inhibited the formation of new blood vessels. In the current work, we studied the stability of ES2-AF after HA modification, including heat stability, longterm stability, and pH stability. After treatment with HA-ES2-AF, cell apoptosis and the cell cycle were analyzed using flow cytometry. The inhibitory effect of HA-ES2-AF on tumors was investigated <i>in vivo</i> in HepG2 tumor-bearing nude mice. All the above results showed that HA-ES2-AF significantly improved stability, effectively induced apoptosis of endothelial cells, caused G1 phase arrest of endothelial cells, and decreased the percentage of cells in G2 and S phases. <i>In vivo</i>, HA-ES2-AF exhibited an inhibitory effect on tumors growth. In addition, the results provide a reliable basis for studying the inhibition of neovascularization and anti-tumor drugs in the future.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Yang</LastName>\n                    <ForeName>Zhifang</ForeName>\n                    <Initials>Z</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Li</LastName>\n                    <ForeName>Yan</ForeName>\n                    <Initials>Y</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sun</LastName>\n                    <ForeName>Feng</ForeName>\n                    <Initials>F</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hou</LastName>\n                    <ForeName>Huiwen</ForeName>\n                    <Initials>H</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Xing</LastName>\n                    <ForeName>Liang</ForeName>\n                    <Initials>L</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wang</LastName>\n                    <ForeName>Zhendong</ForeName>\n                    <Initials>Z</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wang</LastName>\n                    <ForeName>Fengshan</ForeName>\n                    <Initials>F</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tan</LastName>\n                    <ForeName>Haining</ForeName>\n                    <Initials>H</Initials>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Biomed Nanotechnol</MedlineTA>\n            <NlmUniqueID>101230869</NlmUniqueID>\n            <ISSNLinking>1550-7033</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>9004-61-9</RegistryNumber>\n                <NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006820" MajorTopicYN="N">Hyaluronic Acid</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>10</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31219021</ArticleId>\n            <ArticleId IdType="doi">10.1166/jbn.2019.2808</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'